Skip to main content
Figure 2 | Virology Journal

Figure 2

From: FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection

Figure 2

FSL-1 delivered once daily for 5 consecutive days did not induce chronic inflammation. As a marker of an inflammatory state, IL-1α, IL-6 and TNF-α were kinetically quantified in murine lavages of repetitive daily dosed animals (n = 5/treatment). Each cytokine was induced significantly (*, p < 0.05; Student's t-test) 6 h after FSL-1 (6 μg; closed square) application compared to DPBS vehicle (60 μL; open circle). Notably, by 24 h after each FSL-1 dose, induced cytokines had returned to DPBS vehicle levels and were not significantly (p > 0.05; Student's t-test) increased 24 h after the final FSL-1 application. Each collection time point is presented as mean ± SEM of five replicates from two independent experiments.

Back to article page